ZYBERNO
Stock Report
Updated Aug 31, 2026

Renalytix plc (RNLXY)

Healthcare • OTC

$2.66

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
Renalytix plc (RNLXY) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-1,054.9%)
Return on Capital (Capital Efficiency):CRITICAL (-479.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Renalytix plc (RNLXY) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.66
Market Cap:$15.34M

Valuation Multiples (2)

P/S Ratio:6.52x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$14.45M

Price Action & Momentum (1)

% of 52-Week High:23.1%
B. Profitability Assessment

Return Metrics (4)

ROA:-341.7%
Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-9.4%

Margin Analysis (3)

Operating Margin Ttm:-1,054.9%
Net Margin Ttm:-1,191.8%
Ebitda Margin:-1,042.3%

TTM Performance (3)

Gross Margin Ttm:1.1%
Operating Margin Ttm:-1,054.9%
Net Margin Ttm:-1,191.8%

Yield Metrics (2)

Earnings Yield:-$8.56
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-13.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.24x
Quick Ratio:0.24x
Cash Ratio:0.08x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-9,134,000.00
Cash And Cash Equivalents:909,000.00
Long Term Debt:$11.50K
Net Debt:-$886.50K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.35M
Linear Growth: -13.0%
📊 Click to view full RNLXY Revenue analysis & methodology →
Cost Of Revenue Ttm:$2.05M

Profitability Breakdown (2)

$27.00K-$24.81M

Bottom Line Performance (3)

-$28.03M
Income Before Tax:-$28.02M
Ebitda Ttm:-24,515,000.00

Operating Expenses (5)

Operating Expenses:25,110,000.00
R And D Expense:7,424,000.00
Sga Expense:16,963,000.00
Income Tax Expense:$6.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:1,422.2%
Sga To Revenue Percentage:3,249.6%
Ebitda Margin:-1,042.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$4.79M
Current Assets:$2.88M
Ppe Net:202,000.00
Goodwill:0.00
Intangible Assets:$869.00K

Liability Structure (4)

Total Liabilities:16,113,000.00
Current Liabilities:12,013,000.00
Long Term Debt:$11.50K
Short Term Debt:$11.00K

Equity & Capital (3)

Equity:-$11.32M
Retained Earnings:-$216.51M
Common Stock:173,841,695.00

Working Capital Items (3)

Accounts Receivable:902,000.00
Inventory:0.00
Accounts Payable:2,162,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:254,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$24.44M$0.00

Investment Activities (1)

Investing Cash Flow:$23.00K

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:14,900,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:297,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.24
-$0.24
Earnings Per Share Ttm:-$4.86

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.41
Operating Cash Flow Per Share:-$5.22

Book Value & Capital (2)

Book Value Per Share:-$1.96
Cash Per Share:0.16

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.29x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:2.61x
Days Sales Outstanding Ttm:139.98

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:384.38
Cash Conversion Cycle:-1,243.40
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-9.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-13.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:RNLXY
Company Name:Renalytix plc
Sector:Healthcare
Industry:Services-Medical Laboratories
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.77M
Shares Outstanding Basic:105.70M
Shares Outstanding Diluted:105.70M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 03:07:46 UTC
Data Timestamp:2026-08-18T11:14:49.110551
Scroll to Top